Menu
Recruiting NCT04538859

A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong

Observational Bronchiectasis Adult

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Bronchiectasis Adult. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Hong Kong
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Bronchiectasis is associated with repeated exacerbations which occurs at rates of 1.5-6.5 per patients per year, and are associated with an increased risk of admission and readmission to hospital, and high health care costs. In a local study carried out more than 10 years ago, idiopathic disease dominates and patients with bronchiectasis are mainly female with high hospitalization and mortality rates; 21.9 cases per 100,000 and 2.7 cases per 100,000 respectively. Moreover, exacerbation characterized by increases in symptoms requiring antibiotic treatment is associated with disease progression and significant mortality. Updated prevalence of this disease with the characteristics of etiology, clinical presentation and outcomes are needed to guide further management plan.

Primary outcome measures

  • Number of bronchiectasis exacerbation [Time frame: 5 years]
Secondary outcome measures (1)
  • Mortality rate [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • Patients aged 18 years or older
  • Clinically stable for at least 4 weeks prior to enrollment (defined as no symptoms of exacerbation, no requirement for supplemental antibiotic therapy)
  • Diagnosis of bronchiectasis defined by high-resolution computed tomography scan

Exclusion criteria

  • History of cystic fibrosis; hypogammaglobulinemia; allergic bronchopulmonary aspergilosis
  • Those who are unable to give consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Hong Kong · 1 center
  • Chinese University of Hong — Hong Kong

Identifiers

NCT: NCT04538859 · ProBronchiectasis/2019

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗